Abstract
SLC7A11 is highly expressed in various solid tumors, including colorectal cancer and pancreatic cancer. The aim of the study was to report the therapeutic potential of SLC7A11 CAR-T therapy. The SLC7A11-specific antibodies were generated by hybridoma and humanization technologies. The cytotoxicity was validated in vitro through co-culture assays of effector cells with cancer cell lines. The anti-tumor studies in vivo were evaluated by cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models. We first confirmed the tumor specificity of SLC7A11 and then successfully developed SLC7A11-specific CAR-T cells. CCK-8 and LDH cytotoxicity assays demonstrated that cancer cells co-cultured with CAR-T cells exhibited higher mortality rates. Animal experiments showed that SLC7A11 CAR-T treatment suppressed the tumor growth without causing significant abnormalities in blood biochemical parameters. In conclusion, SLC7A11 CAR-T cell therapy showed remarkable anti-tumor capabilities and safety in colorectal and pancreatic cancer.